Imunon, Inc. (IMNN): Nasdaq/NYSE listing notice — Imunon regains Nasdaq minimum bid price compliance; trading continues uninterrupted

Imunon, Inc.

Received Nasdaq Hearings Panel confirmation of regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
Common stock (IMNN) to continue trading on Nasdaq Capital Market without interruption.
CEO notes recent 15% stock dividend and momentum from Phase 2 OVATION 2 trial for IMNN-001 in ovarian cancer.
Phase 3 OVATION 3 trial for IMNN-001 successfully initiated in North America.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Imunon, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-012417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.